Plasma infusion in the treatment of thrombotic thrombocytopenic purpura

Research output: Contribution to journalArticlepeer-review

32 Scopus citations


Fifteen of 18 patients with clinically diagnosed or pathologically proven thrombotic thrombocytopenic purpura (TTP) responded favorably to plasma infusions. Thirteen remained alive and well. The amount of plasma necessary to produce control of the disease varied widely. Other modalities of treatment were employed in many of the cases, and may have contributed some benefit. These included plasmapheresis, corticosteroids, and antiplatelet agents. The first indicator of a good response to plasma infusion was a rise in platelet count. Platelet transfusions are contraindicated, since they have been associated with rapid clinical deterioration and death. Since hypervolemia can become a severe problem in TTP patients whose plasma requirement is high, it would be helpful to identify and concentrate the therapeutically active plasma fraction. (E.J. van Slyck, Detroit, USA).

Original languageEnglish (US)
Pages (from-to)9-14
Number of pages6
JournalSeminars in Thrombosis and Hemostasis
Issue number1
StatePublished - Jan 1 1981

ASJC Scopus subject areas

  • Hematology
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Plasma infusion in the treatment of thrombotic thrombocytopenic purpura'. Together they form a unique fingerprint.

Cite this